The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
Official Title: A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction Versus (VS) Standard-Fractionated IMRT, Concurrent With Carboplatin/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects With Stage 2A/B Non-Small Cell Lung Cancer
Study ID: NCT04992780
Brief Summary: The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas, United States
KUCC MCA- TUKHS, Saint Francis Hospital, Topeka, Kansas, United States
The University of Kansas Cancer Center, North Clinic, Kansas City, Missouri, United States
The University of Kansas Cancer Center, Lee's Summit Clinic, Lee's Summit, Missouri, United States
University of Kansas Cancer Center, North Kansas City Hospital, North Kansas City, Missouri, United States
Name: Krishna Reddy, MD, PhD
Affiliation: University of Kansas Medical Center
Role: PRINCIPAL_INVESTIGATOR